Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A marketed **combination injection kit** containing **methylprednisolone acetate**, a depot glucocorticoid corticosteroid; **lidocaine**, a local anesthetic; and **isopropyl alcohol**, an antiseptic skin-preparation component. The therapeutic activity is driven primarily by methylprednisolone acetate, which acts as a **glucocorticoid receptor agonist** to suppress inflammatory and immune signaling, while lidocaine provides local anesthesia and isopropyl alcohol is used for procedural antisepsis. Based on the provided context, this kit is manufactured by **Amneal Pharmaceuticals** and is used around intramuscular, intra-articular, soft tissue, and intralesional administration settings for inflammatory and rheumatologic disorders such as acute gouty arthritis, bursitis, tenosynovitis, epicondylitis, rheumatoid arthritis, and synovitis of osteoarthritis, as well as selected intralesional dermatologic conditions including alopecia areata, discoid lupus erythematosus, keloids, granuloma annulare, lichen planus, lichen simplex chronicus, psoriatic plaques, and necrobiosis lipoidica diabeticorum.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isopropyl alcohol + methylprednisolone acetate + lidocaine.